Human host cells and immune system

The "Human host cells and immune system" refers to the integrated network of cells, tissues, and molecular pathways that defend the human body against pathogens and internal threats like cancer (Source: StatPearls, NBK459471). In the context of drug development, this entity is not a single molecular target but rather a broad therapeutic domain encompassing host-directed therapies (HDTs). These therapies aim to manipulate the host's own biological processes to achieve a therapeutic outcome, such as enhancing protective immunity or limiting tissue damage from excessive inflammation (Source: PubMed, PMID: 32275918). Key components include various immune cell types like T-cells and macrophages, as well as signaling molecules like cytokines (Source: NIH, PMC7120473). Drugs interacting with this system include immunomodulators, checkpoint inhibitors, and anti-inflammatory agents, which work by altering host signaling cascades (Source: Nature Reviews Drug Discovery, doi:10.1038/nrd.2017.231). Because this "target" represents the entire physiological defense apparatus, therapeutic intervention requires careful calibration to avoid severe side effects like systemic immunosuppression or cytokine storms.

Other names

Host factorsHuman immune systemHost-pathogen interfaceHost-directed therapy targets

Modulation of host cellular pathways, signaling cascades, and immune cell activity to enhance defense mechanisms or reduce pathological inflammation (Source: PubMed, PMID: 32275918).